Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and tolerability of an investigational drug called elritercept, both alone and in combination with the JAK inhibitor ruxolitinib, in adults with myelofibrosis MF. The study also aims to understand how elritercept affects the signs and symptoms of MF, how the body processes the drug, and its effects on anemia when used with or without ruxolitinib. This is a Phase 2 open-label study focusing on participants with anemia related to MF.
Actively Recruiting
Non-muscle-invasive bladder cancer NMIBC is a type of bladder tumor that affects the inner lining of the bladder without invading the muscle layer. This research aims to collect and analyze real-world data on how NMIBC is managed and followed up in clinical practice across France. The study seeks to assess the performance of urine tests used to detect tumor recurrence and to understand variations in treatment and patient outcomes. The study is observational and involves collecting medical data from patients being monitored for NMIBC, including results from urine biomarker tests done before biopsies or resections. Urologists participating in the French Urology Association will record findings from regular bladder endoscopic exams and urine test results during routine care visits. Data analysis will focus on the accuracy of urine tests in predicting tumor recurrence and how this varies by tumor characteristics and prior treatments. Participants will have their medical history, treatments, and urine test results entered into a registry at enrollment. During follow-up visits scheduled as part of their personalized care, data on bladder exams and urine tests will be collected. Researchers will evaluate outcomes such as recurrence-free survival and the diagnostic value of urine biomarkers over a five-year period. The study plans to include around 8,000 patients over six years to improve understanding of NMIBC management and follow-up.
Actively Recruiting
Philadelphia-negative myeloproliferative neoplasms MPNs such as Polycythemia Vera, Essential Thrombocythemia, and Prefibrotic Myelofibrosis are chronic blood cancers caused by mutations affecting blood cell growth. These diseases carry a high risk of blood clots, which can cause serious complications and death. Current treatments include low-dose aspirin, but blood clots still occur in some patients despite therapy. This trial aims to study whether direct oral anticoagulants DOACs, which have shown benefits in other cancer patients, might help prevent blood clots in MPN patients with a specific mutation called JAK2V617F. Participants will be randomly assigned to receive either a direct oral anticoagulanteither Apixaban 2.5 mg twice daily or Rivaroxaban 10 mg once dailyor low-dose aspirin 100 mg once daily. The choice of DOAC is up to the investigator. The treatments will be given to high-risk patients for up to 24 months to compare their effects on clot prevention. Throughout the study, participants will be closely monitored for any thrombotic or bleeding events. During the trial, researchers will track the time until any arterial or venous blood clots occur, as well as any major or clinically relevant bleeding events. They will also evaluate survival, adherence to therapy, quality of life, and healthcare costs related to these treatments. Participants will have regular follow-ups over 24 months, including assessments for heart rhythm problems and safety monitoring. This comprehensive approach aims to better understand the benefits and risks of DOACs compared to aspirin in preventing clots in MPN patients.
Actively Recruiting
This research aims to evaluate the effectiveness of a hypnotherapy method called E2R in treating chronic insomnia in primary care. Chronic insomnia in France is mostly managed with hypnotic drugs, which can cause side effects. Cognitive-behavioral therapy is recommended as a first-line treatment but is not widely used. The study compares E2R hypnotherapy to standard care without hypnosis in adults with chronic insomnia. Participants will be randomized into two groups one receiving four 30-minute hypnotherapy sessions over six weeks using the E2R method, and the other receiving standard care from their general practitioner, which may include psychotherapy or medication but excludes hypnosis. The hypnotherapy group will have sessions with a local hypnotherapist within a 30-minute travel radius. Participants will be assessed at three and six months after starting the study. Evaluations include questionnaires on insomnia severity and sleep quality, records of medication and other therapies used, patient diaries on self-hypnosis practice, and monitoring for neuropsychiatric adverse events. The study will measure changes in insomnia severity using the Insomnia Severity Index, with safety and treatment response also tracked over six months.
Actively Recruiting
Researchers are evaluating the combination of luspatercept and erythropoiesis stimulating agents ESA for adults with lower-risk myelodysplastic syndrome LR-MDS without ring sideroblasts who have not responded to or are not eligible for ESA treatment. The trial is designed as a randomized Phase III study to determine the best dose and assess whether the combination is more effective than luspatercept alone. Participants receive luspatercept as a subcutaneous injection every three weeks, with doses adjusted in the dose-finding phase. In some groups, luspatercept is combined with weekly epoetin alfa Eprex injections at specified doses. The trial has two parts Part A focuses on finding the optimal dose for safety and effectiveness, and Part B compares the combination treatment to luspatercept alone in patients who did not respond or relapsed after ESA treatment. Throughout the study, participants undergo regular monitoring for toxicity and response at planned time points including evaluation of dose-limiting toxicities early on and assessing benefits by week 25. Secondary outcomes include response rate, duration of response, and overall survival tracked up to 30 months. The study requires adherence to scheduled visits and safety assessments, with informed consent and performance status evaluation at screening.